1 surging penny stock I’d buy today at 32p

This AIM-listed penny stock has climbed 51% in 2023 so far after delivering an increase in profits and a reduction in net debt.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

British Pennies on a Pound Note

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Penny stocks are volatile-but-potentially-lucrative investments. And I’ve recently been looking for smaller companies to invest in to complement the larger firms that form the majority of my portfolio.

One business that caught my eye is Iofina (LSE:IOF), which specialises in the exploration and isolation of iodine as well as the production of speciality chemicals. At present, the company’s shares trade for 32p each and it has a market capitalisation just shy of £61m.

Here’s my take on the outlook for this penny stock.

A mineral in demand

Iodine is essential for human health. It plays a vital role in proper thyroid functioning and promoting hormone production for healthy metabolism. It’s estimated that up to a third of people worldwide are at risk of an iodine deficiency.

The price of iodine has risen steadily since early 2020, driven by demand for human health applications and X-ray contrast imaging agents. Analysts expect the market will continue to grow over the coming years.

This is good news for Iofina. The company has developed a method of extracting iodine from leftover brine in onshore oil and gas production. Its process is more environmentally friendly and cheaper than leaching nitrate ores mined from the Atacama Desert, which is the source of around 66% of the world’s iodine supply.

Strong financials

The company’s results for FY22 were encouraging. Revenue increased 8% to $42.2m and its average price per kilogram for sales of crystallised iodine rose 98% to an average of $71.20. In fact, the group saw improvement across a range of key metrics including EBITDA, profits, and cash flow.

In addition, the business also trimmed its net debt from $3m to $0.9m. This is a positive sign, considering Iofina’s balance sheet hasn’t always been this healthy. After rapid expansion in 2013, the share price had collapsed 98% by early 2016, weighed down by large debts and loss-making operations.

Regarding future expansion, the company’s focus is on expanding iodine production and its speciality chemicals business. It aims to develop new chemical compounds, reduce its reliance on its current oil and gas partners, and explore new geographic areas. It currently operates five extraction facilities in the Anadarko Basin in western Oklahoma.

Risks

Of course, Iofina is very exposed to iodine prices. Any turbulence in the market poses a clear risk if the company’s margins are squeezed as a result.

Moreover, although the firm has good relationships with energy companies operating in Oklahoma’s oil fields, there’s a limited number of fields that can be developed in the area. That said, the company isn’t near full capacity currently. Plus, it plans to diversify its revenue sources in the future.

Nonetheless, as things stand, this could potentially curtail long-term growth in the share price.

Why I’d buy this stock

Overall, it looks attractively valued to me and recent financial results have been very positive. If global demand for iodine continues to grow as the company expects, there’s considerable potential for the business to expand.

While I wouldn’t take too large a stake in any penny stock, given their volatile nature, this company could potentially help to boost my portfolio’s returns. If I had spare cash, I’d buy today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Charlie Carman has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

Prediction: this will be the FTSE 100’s next great stock!

This FTSE 250 stock has more than doubled in value during the past five years. Our writer thinks it could…

Read more »

Yellow number one sitting on blue background
Investing Articles

Billionaire Bill Ackman has just 1 magnificent AI stock in his FTSE 100-listed fund

Our writer takes a look at the only AI stock held in the portfolio of FTSE 100-listed Pershing Square Holdings.

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

2 penny stocks this Fool thinks could deliver phenomenal returns!

Penny stocks are a risky but exciting asset class to invest in, prone to wild volatility. Our writer thinks he's…

Read more »

Buffett at the BRK AGM
Investing Articles

I’ve just met Warren Buffett’s first rule of investing. Here are 3 ways I did it

Harvey Jones has surprised himself by living up to Warren Buffett's most important investment rule. But is his success down…

Read more »

Engineer Project Manager Talks With Scientist working on Computer
Investing Articles

Down 51% in 2024, is this UK growth stock a buy for my Stocks and Shares ISA?

Ben McPoland considers Oxford Nanopore Technologies (LSE:ONT), a UK growth stock that has plunged over 80% since going public in…

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

These 3 growth stocks still look dirt cheap despite the FTSE hitting all-time highs

Harvey Jones is hunting for growth stocks that have missed out on the recent FTSE 100 rally and still look…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

Here’s how much I’d need to invest in UK income stocks to retire on £25k a year

Harvey Jones is building his retirement plans on a portfolio of top UK dividend income stocks. There are some great…

Read more »

Investing Articles

If I’d invested £5,000 in BT shares three months ago here’s what I’d have today

Harvey Jones keeps returning to BT shares, wondering whether he finally has the pluck to buy them. The cheaper they…

Read more »